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Abstract
Insulin therapy is only effective if it is delivered into the right tissue in the right way. 
Exogenous insulin is intended for the subcutaneous (SC) tissue, not the muscle or skin. If 
delivered into the latter, its absorption (pharmacokinetics (PK)) and action (pharmacody-
namics (PD)) are unpredictable, which often leads to poor glucose control. Correct insulin 
therapy begins with matching the insulin to the site used. Typically, four sites are used 
for insulin injection or infusion: the abdomen lateral to the umbilicus all the way to the 
flanks, the anterior lateral upper half of the thigh, the deltoid region of the arm, and the 
upper outer quadrant of the buttocks. Regular insulin and neutral protamine Hagedorn 
(NPH) are both absorbed more rapidly from the arm and abdominal sites and more slowly 
from the thigh and buttocks. The newer insulin analogs, both rapid- and slow-acting, do 
not appear to be influenced by the site used for injection. In order to avoid intramuscular 
(IM) injections, patients should use the shortest needles currently available (the 4-mm pen 
needle and the 6-mm syringe needle). Very young children should raise a skin fold and 
inject into it even when using the 4-mm needle. Giving injections with the 6-mm needle at 
a 45° angle converts this needle into the equivalent of the 4 mm. Injection sites should be 
rigorously rotated, with the new injection being approximately 1 cm from previous injec-
tions. This measure helps prevent the most common complication of injection therapy, lipo-
hypertrophy (LH). Injecting into LH leads to unstable PK and PD and deregulated glucose 
control, manifested as unexpected hypoglycemia, glycemic variability, and elevated HbA1c 
values. Comprehensive insulin deliver recommendations have recently been published.
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1. Introduction
Current insulin therapy requires delivery into the subcutaneous (SC) tissue either by injec-
tion or by infusion. Optimal insulin delivery requires that accidental intramuscular (IM) or 
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 intradermal (ID) delivery be avoided since the pharmacokinetics (PK) and pharmacodynamics 
(PD) of insulin are significantly altered in these tissue spaces. Optimal delivery also requires 
that sites of injection or infusion be rotated systematically in order to avoid the most common 
complication of insulin therapy, lipohypertrophy (LH). Insulin delivered into LH also has sig-
nificantly altered PK and PD, which can lead to unexpected hypoglycemic episodes and gly-
cemic variability. The latter are associated with worsened overall glucose control, increased 
short- and long-term complications, and higher costs.
Recently, new recommendations have been published as a consensus document from inter-
national diabetes experts [1]. This publication was the collective output of 183 experts from 54 
countries who wrote and vetted a practical, evidence-based roadmap for optimal insulin deliv-
ery at the FITTER (Forum for Injection Technique and Therapy: Expert Recommendations) 
workshop from October 23 to 24, 2015, in Rome. FITTER was the fourth in a sequence of 
workshops on optimal insulin delivery [2–4]. The FITTER recommendations were also based 
on the results of the fourth Injection Technique Questionnaire (ITQ) survey conducted from 
2014 to 2015. In total, 13,289 insulin-injecting patients from 42 countries participated [5].
Each recommendation is followed by a grade (e.g., A2). The letter indicates the strength of 
each recommendation: A. Strongly recommended; B. Recommended; C. Unresolved issue. 
The number indicates the degree of scientific support for each recommendation: 1. At least 
one rigorously performed study which is peer-reviewed and published; 2. At least one obser-
vational, epidemiologic, or population-based study which is peer-reviewed and published; 3. 
Consensus expert opinion based on patient experience. Since FITTER, many diabetes groups 
from countries around the world have adapted and adopted these recommendations as local 
guidelines. We draw on certain of these recommendations in the review that follows as well as 
summarize studies that have been performed since FITTER and will follow a thematic format, 
beginning with the anatomy of injection sites.
2. Current insulin delivery practice
A large survey of current insulin delivery has shown that there are many aspects of injection 
practice which are suboptimal [5, 6]. For decades, professionals had been advising patients to 
use insulin needles which, we now know, were too long for them, with no scientific rationale. 
However, after the shortest pen needles (4 mm) became available and studies on injection site 
anatomy and needle performance began to be published, starting in 2010 [7, 8], showing the 
safety and efficacy of these needles, the recommendations of experts changed. It was recog-
nized that 4-mm pen needles were the optimal choice for nearly all injecting patients, whether 
adults or children: thin, normal-weight or obese, male or female, and of all ethnicities. These 
needles were felt to be a key step toward reducing the risk of IM injections. As a result, the use 
of the 8-mm needle, the dominant size in 2010, has decreased dramatically since then, with a 
corresponding increase in the use of the 4-mm needle.
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However, the latest survey revealed that the longer lengths (8 mm and higher) are still being 
used by approximately 30% of patients worldwide and that the 5- and 6-mm needles are 
still used by approximately 20% each. This means that only 30% of patients worldwide cur-
rently use the recommended 4-mm needles. Longer needles are being used in sites where 
IM injection risk is very high (thighs and arms) and by patients who are at an increased risk 
because they have thin SC layers (slim and normal-weight adults as well as all adolescents 
and children).
The same survey has shown that lipohypertrophy (LH) is very common at injection sites. 
LH was found in almost a third of patients worldwide, many of them having LH at multiple 
injection sites. Injecting into LH has serious consequences for glucose control as well as pos-
sibly adverse effects on long-term outcomes and costs. Patients with LH consume a mean of 
over 10 IU more insulin per day than those without LH, and their HbA1c is on average 0.55% 
higher. LH is associated with increased rates of unexplained hypoglycemia, glucose variabil-
ity, and more frequent diabetic ketoacidosis (DKA).
The survey showed that LH is most frequently associated with an incorrect rotation of 
injection sites and reusing pen needles. Rotating injection sites carefully appears to be the 
best method of avoiding LH. HbA1c values are lower in patients who rotate their injec-
tions over larger injection areas and who get their sites inspected regularly. Checking of 
injection sites routinely by health-care givers is associated with less LH and lower HbA1c 
levels, yet nearly 40% of patients reported that they could not remember their injection 
sites ever being examined. Patients are also more likely to rotate correctly if they have 
obtained injection instruction from their carer in the last 6 months. However, less than 
two out of five claim to have obtained such instructions on injecting in that time period. 
Ten percent of total injectors claim that they have never obtained injection training at all. 
The survey also shows that incorrect disposal of sharps after use is rampant. The major-
ity of used sharps end up in public trash and constitute a major risk factor for accidental 
needle sticks.
3. Skin thickness
The skin is the main obstacle the needle must overcome. Needles must be at least long enough 
to traverse the skin and reach the SC tissue. Adult skin, according to a number of studies 
using imaging techniques ranging from ultrasound (US) to computer tomography (CT), has 
yielded remarkably similar results across genders, ethnicities, age groups, and body mass 
index (BMI) categories. The skin averages approximately 2–2.5-mm thick and varies in its 95% 
confidence interval (CI) between 1.25 and 3.25 mm. These studies included patients with type 
2 diabetes (T2DM) from the Philippines [9], Korea [10], China [11], and India [12]; both type 1 
diabetes (T1DM) and T2DM adults from the USA (including four different ethnic groups) [7]; 
and children from South Africa [13] and Italy [14].
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The skin in children is slightly thinner than in adults, but these differences are largely irrel-
evant for insulin infusions and injections. Skin thickness increases during adolescence and 
reaches adult size in the late teens.
4. SC thickness
The SC tissue is the target for insulin. Injections must reach the SC tissue, but not go deeper 
into the muscle fascia or the muscle itself. Therefore, the thickness of the SC is critical in 
determining the desired length of the needle as well as the injection technique (e.g., lifting 
a skin fold or not). SC tissue thickness varies widely depending on gender, site of injection, 
and BMI. Women, on average, have approximately 5-mm thicker SC fat than men, when 
one controls for BMI and body site. Truncal sites (abdomen and buttocks) have more SC fat 
than limbs (arm and thigh), in the same patient. The higher the BMI, the thicker the SC fat. 
Studies within the last decade have used precision US to determine the SC tissue thickness in 
a diverse group of adults [7, 9, 15, 16], adolescents, and children [13, 14].
Marran, 2014 [13] Lo Presti, 2014 (pooled) [14]
Arm Thigh Abdomen Buttock Ages
2–6
Ages
7–13
Ages
14–17
4 mm 27.5% 12.5% 12.5% 0% 20.2% 4.6% 2.4%
5 mm 47.5% 22.5% 30.0% 0% 46.0% 18.4% 16.1%
6 mm 62.5% 30.0% 37.5% 5.0% 66.5% 38.0% 34.5%
8 mm 87.5% 62.5% 50.0% 15.0% 83.9% 65.3% 66.1%
12.7 mm 100% 90.0% 85.0% 35.0% 97.2% 93.9% 96.4%
*Assumes that injections are into flat skin and not into lifted skin fold.
Table 2. Calculated risk of IM injection in children and adolescents as a function of injection site, age, and needle length*.
Needle length Combined Thigh Arm Abdomen Buttock
4 mm 0.4% 1.6% 1.0% 0.3% 0.1%
5 mm 1.8% 4.7% 3.1% 1.1% 0.5%
6 mm 5.7% 10.0% 7.0% 2.8% 1.3%
8 mm 15.3% 25.0% 19.5% 9.7% 5.5%
12.7 mm 45.0% 63.0% 55.0% 38.0% 26.9%
*Assumes injection straight at 90° without pinch-up (the table adapted from Hirsch [16]).
With kind permission from Hirsch L et al. [16]. Intramuscular risk at insulin injection sites—measurement of the distance 
from the skin to the muscle and rationale for shorter-length needles for subcutaneous insulin therapy.
Table 1. Estimated IM injection risk in adults, by body site*.
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Babies have more SC tissue than preschool children. Children from 2 to 6 years have very little 
SC tissue regardless of gender. Children from 7 to 13 years gain SC tissue slowly but SC tissue 
thickness is almost the same in both genders until puberty. At puberty, girls increase their SC 
tissue more rapidly than boys as a result of hormonal differences.
SC tissue thickness when combined with the currently available needle lengths yields a rela-
tively clear indication of the risk of IM injection. Tables 1 and 2 show the risks for adult and 
pediatric persons with diabetes, respectively. It is clear from these data that the shorter the 
needle, the lower the risk of IM injection.
5. IM insulin
IM-injected insulins have a much greater variability in absorption and effect (PK and PD) 
compared to SC-injected. This variability is influenced by both exercise and the properties 
of the individual insulins. Human insulins and the new analogs also differ as to their PK 
when injected IM. In general, IM insulin is often associated with a more rapid absorption 
and unexplained hypoglycemia [17–19]. Because of the difficulty of predicting the impact 
of IM injections on PK and PD, various measures can be taken to avoid injecting IM: using 
of shorter needles, lifting of a skin fold into which one injects the insulin, or choosing injec-
tion sites with thicker layers of SC fat. A combination of the above techniques can also be 
used [20].
6. Needle length
In the last decade, insulin needle lengths have decreased dramatically. Previously, adults 
were given needles that were ≥ 8 mm long and children ≥6 mm. As shown in Tables 1 and 2, 
these lengths are now universally recognized as too long. They make IM injections more 
likely, and on the whole, the length of the needle has little or nothing to do with glucose 
control, according to a multitude of studies [8, 21–28]. Longer needles also tend to have larger 
diameters (smaller G or gauge), which correlates with a greater injection pain.
Hirsch [8] compared the 4-mm pen needle to 5- and 8-mm needles and showed the former to 
be safe and efficacious in adults (i.e., comparable glucose control); leakage from the skin was 
equivalent and both pain scores and overall preference were better with the 4 mm. In Japan, 
Miwa [29] compared the 4-mm needle with 6 mm and showed equivalent results, as did 
Nagai [30] when comparing 4-to 5-mm pen needles. Hirose [31] found equivalent modeled 
PK/PD results for the 4 mm compared to the 6- and the 8-mm needles, in young non-diabetics. 
Birkebaek [32] found a reduced IM risk with 4 versus 6-mm PNs in children and lean adults. 
Lo Presti [14] measured the skin and SC in children and adolescents with diabetes (ages 2–17) 
and concluded that the safest needle length for all ages is the 4 mm.
In obese adults, Bergenstal [33] recently showed that the 4-mm pen needles deliver equivalent 
glycemic control (HbA1c) to both 8- and 12.7-mm pen needles. These obese patients were taking 
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relatively high doses of glargine (>40 IU), with total daily dose (TDD) insulin up to 300 U daily. 
No differences between 4- and both 8- and 12.7-mm PNs in hypo- or hyperglycemic events or 
insulin leakage were found in obese subjects with BMI up to nearly 60 kg/m2. The 4-mm needle 
was found to be less painful, easier to use, easier to insert, and less anxiety-provoking than 8 or 
12.7 mm (all at p < 0.05).
Based on these studies, FITTER recommended the following:
• The 4-mm needle inserted perpendicularly is long enough to penetrate the skin and enter 
the subcutaneous tissue, with little risk of intramuscular (or intradermal) injection. There-
fore, it should be considered the safest pen needles for adults and children regardless of 
age, gender, ethnicity, and BMI. A1
• The 4-mm needle should be inserted perpendicular to the skin (at 90° to the skin surface), 
not at an angle, regardless of whether a skin fold is raised. A1.
• Very young children (6 years old and under) and very thin adults should use the 4-mm 
needle by lifting a skin fold and inserting the needle perpendicularly into it. Others may 
inject using the 4-mm needle without lifting a skin fold. A1
• Patients with tremors or other disorders, which make them unable to hold a 4-mm pen 
needle in place, may need longer needles. B3
7. Injection site care
Recommended injection sites include the abdomen, lateral thigh, arms, and buttocks [34–38]. 
In the abdomen, injections or infusions in adults may be given within the following boundar-
ies: 1 cm above symphysis pubis, 1 cm below the lowest rib, 1 cm away from the umbilicus, 
and laterally at the flanks. In the lateral thighs, patients should use the upper third anteriorly. 
The posterior lateral aspect of the upper buttocks and flanks may be used. In the arm, one 
may use the mid-third posterior aspect. In children, the abdominal boundaries are similar to 
adults, but 2 cm is used instead of 1 cm for all distances. A degree of clinical judgment must 
be used in all cases, adult and pediatric.
8. Human insulin
Soluble human insulin (e.g., regular insulin) has a slower absorption profile than the rapid-
acting analogs (lispro, aspart, and glulisine). The PK and PD of regular insulin, as well as 
those of neutral protamine Hagedorn (NPH), are highly dependent on the body site injected 
and the technique used. FITTER recommendations state that:
• IM injections of NPH and long-acting insulin analogs must be strictly avoided due to the 
risk of hypoglycemia [17, 39–41]. A2
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• The abdomen is the preferred site for soluble human insulin (regular), since absorption of 
this insulin is fastest there [35, 42–46]. A1
• The regular/NPH mix should be given in the abdomen to increase the speed of absorption 
of the short-acting insulin in order to cover postprandial glycemic excursions [18]. A1
• If there is risk of nocturnal hypoglycemia, NPH- and NPH-containing mixes given in the 
evening should be injected into the thigh or the buttock as these sites have slower absorp-
tion of NPH [38, 47, 48]. A1
9. Insulin analogs
There are fewer studies of optimal delivery methods for the newer insulin analogs and 
GLP-1 s. However, insulin analogs are not as dependent on injection sites as are human insu-
lins or NPH. From the existing studies, FITTER recommended the following:
• Rapid-acting insulin analogs may be given at any of the injection sites, as absorption rates 
do not appear to be site-specific [49–53]. A2
• Rapid-acting analogs should not be given IM although studies have shown that absorption 
rates are similar from fat tissue and resting muscle. Absorption from working muscle has 
not, however, been studied [50, 51, 54]. A2
• Pending further studies, patients may inject long-acting insulin analogs in any of the usual 
injecting sites, with appropriate technique to prevent IM injection which can lead to pro-
found hypoglycemia [55]. B2
10. GLP-1 agents
• Pending further studies, patients using non-insulin injectable therapies should follow the 
recommendations already established for insulin injections with regards to needle length, 
site selection, and site rotation [56–58]. A2
11. Lipohypertrophy
LH is the most common complication of insulin injection [59–62] or infusion [63, 64], with 
prevalence rates of 50% or higher. Risk factors for LH appear to be longer time on insulin, 
more daily injections, failure to carefully rotate injection sites, and extensive reuse of nee-
dles [59, 65–68]. The latter two risk factors are modifiable. Insulin injected into LH has been 
reported to have delayed or erratic absorption which may worsen glucose control, although 
these trials are older with less rigor, less precise insulin assays, or very small sample sizes 
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which in one case led to a conclusion that injecting into LH did not worsen inherent variabil-
ity of insulin uptake [69–72]. A crossover glucose clamp study [73] showed that both insulin 
absorption and action when injected into LH are blunted and are 3–5X more variable than 
when the same insulin dose is injected into non-LH areas. A controlled mixed-meal tolerance 
test in the same study also showed a reduced insulin absorption, and prolonged postprandial 
hyperglycemia when the insulin was injected into the LH area. When patients change from 
delivering insulin into LH and move to normal tissue, they are at risk of hypoglycemia and 
must lower their doses. Gentile [74, 75] has shown convincingly that HCPs trained to detect 
LH can do so with extremely high efficiency using the physical examination alone, achieving 
up to 97% consistency levels. FITTER issued the following recommendations:
• Switching injections from lipohypertrophy to normal tissue often requires a decrease in the 
dose of insulin injected. The amount of change varies from one individual to another and 
should be guided by frequent blood glucose measurements. Reductions often exceed 20% 
of their original dose [66, 76]. A1
• Injections should be systematically rotated in such a way that they are spaced at least 1 cm 
(or approximate width of an adult finger) from each other in order to avoid repeat tissue 
trauma. A2
• One scheme with proven effectiveness involves dividing the injection site into quadrants 
(or halves when using the thighs or the buttocks), using one quadrant per week and mov-
ing quadrant to quadrant in a consistent direction (e.g., clockwise) [77]. A3
A multicenter interventional study in the UK [78] showed that education focused on these 
recommendations resulted in significantly reduced clinically detectable LH after 6 months, 
with LH either disappearing completely or decreasing by approximately 50% from its origi-
nal size. The mean HbA1c fell by more than 4 mmol/L, and there were significantly reduced 
levels of unexpected hypoglycemia and glycemic variability. The mean TDD of insulin in the 
study population fell by an average of 5.6 IU by study close.
In a controlled, prospective, multicenter study in French patients [79], all of whom had LH, the 
intervention consisted of instructions to move injections to non-LH areas, to correctly rotate 
within injection sites, to forego needle reuse, and to switch to 4-mm needles in order to facili-
tate correct rotation without increased IM injections. These patients were also given intensive 
education on the injection recommendations as summarized in this chapter. Control patients 
were informed of the presence of LH and were told that injections should not be given into 
LH. They received usual and standard education. In the intervention group, there was a signifi-
cant decrease of TDD of insulin of approximately 5 IU versus baseline (P = 0.035). There were 
significant decreases in HbA1c (up to 0.5%) in both intervention and control groups, with no 
significant differences between groups. A significant number of intervention patients improved 
their IT habits. The authors concluded that the intervention was effective in both groups, but 
that intensive education in LH management yielded more rapid and superior outcomes.
Ultimate Guide to Insulin64
An interventional study in Moscow [80] followed three groups of T1DM and T2DM patients 
for 6 months. Two groups received structured injection training (with one group receiving 
4-mm needles for each injection while the other did not) and a control group which did not 
get training or needles. Both training groups had HbA1C reductions of approximately 1% but 
the non-training group saw no change. Needle reuse and LH declined in the training groups 
and injection technique improved but none of these changes were seen in the non-training 
group.
The available data from intervention trials in patients with insulin-related LH show consis-
tently positive outcomes. However, there are limitations to each trial—some were not random-
ized; in another, the control group received meaningful parts of the educational intervention 
[79]. Results of one or more ongoing randomized clinical trials should provide more definitive 
answers to the impact of injection technique training in the near future.
12. Needle reuse
Reusing needles is a common practice of injecting patients, mainly for reasons of convenience 
and cost-saving. However, a number of studies have linked needle reuse to LH [59, 65, 66, 
81–83], especially when the reuse is excessive (≥5 times/needle). Injection pain was associated 
with reuse in one study [84] although another one disputed these results [85]. Another study 
found bacterial growth on reused needles and inflammatory changes (skin redness) at injec-
tion sites of patients who reused needles [86, 87]. Although local infections or abscesses have 
not been reported with needle reuse, FITTER recommends against reusing needles, which are 
labeled by regulatory agencies for single use.
13. Safety
Patients should never share insulin pens, whether in the hospital or at home setting. Blood 
can be aspirated back into the pen cartridge even after one injection, and this could possibly 
transmit a blood-borne disease such as HIV or hepatitis to the next user. Sonoki [88] found 
hemoglobin in a number of cartridges which patients had used only once. Le Floch [89] also 
studied the contamination of cartridges after one use and found similar findings. A recent US 
study corroborated these findings [90]. The rule with insulin injections is clear: one patient/
one insulin pen.
Insulin needles are the most commonly used sharp worldwide. If not disposed of properly, 
needle-stick injuries with used insulin needles could transmit hepatitis, HIV, or other blood-
borne pathogens. This is a major public health issue. Technologies exist to minimize this risk. 
FITTER recommended the following to minimize the risk of needle-stick injuries, particularly 
in a hospital or other inpatient setting:
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• Safety-engineered devices play a critical role in protecting injectors, pump users, and 
downstream workers [91]. A1
• Needle recapping should not be done. A2
• Sharp containers must be easily accessible at the point of care beside the patient, prior to 
the injection or infusion. A2
• Safe disposal should be taught to patients, caregivers, and all others who may come in 
contact with the sharp device from the beginning of injection or infusion therapy and rein-
forced throughout [92] A2
• Under no circumstance should sharps material be disposed of into the public trash or rub-
bish system. A3
14. Insulin infusion
Continuous subcutaneous insulin infusion (CSII) has been used for 40 years [93, 94]. Insulin 
infusion sets (IISs) deliver insulin into the SC, and they have been associated with numerous 
adverse side effects [95]. It is generally agreed that if a patient has otherwise unexplained 
hyperglycemia, they should administer a correction bolus via their pump. If the blood glucose 
does not decline at least 50 mg/dL by 90 min, they should (1) remove the set, (2) give a cor-
rection with a pen or a syringe, and (3) insert a new set. FITTER recommended the following 
additional recommendations for CSII and IIS users:
• CSII cannula should be changed every 48–72 h in order to minimize infusion site adverse 
events and potential metabolic deterioration. However, these times are very patient-depen-
dent and should be adjusted accordingly. A1
• All CSII patients should be taught to rotate infusion sites along the same principles that 
injecting patients are taught to rotate injection sites. A1
• Any CSII patients with unexplained glucose variability including frequent hypoglyce-
mia/hyperglycemia should have infusion sites checked for lipohypertrophy, nodules, 
scarring, inflammation, or other skin and SC conditions that could affect insulin flow or 
absorption. A1
15. Conclusion
Insulin has a very low therapeutic index. The margin between its greatest therapeutic benefit 
and its unacceptable side effects is low. Without careful attention to optimal insulin delivery, 
patients can find themselves on either side of a slippery slope: either suboptimal therapeu-
tic benefit or high toxicity. Optimal insulin delivery is complex and involves choices that 
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patients and professionals may not have previously considered: the choice of injection sites 
as a function of the insulin delivered, the choice of needle length as a function of SC thick-
ness, the injection or infusion technique which ensure consistently effective SC delivery, the 
precise and systematic rotation of delivery sites, reduced or non-reuse of sharps, and safe 
disposal of used sharps which reduces needle-stick injury risk to family members or the com-
munity at large [96]. We have provided both evidence-based recommendations and proof 
that these work in practice and deliver insulin with an improved therapeutic index and better 
outcomes—both clinical- and patient-reported. The challenge now is to scale these recom-
mendations so that all insulin-using patients and insulin-prescribing professional know and 
follow them.
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Abbreviations
BMI body mass index
CSII continuous subcutaneous insulin infusion
DKA diabetic ketoacidosis
FIT Forum for Injection Technique
FITTER Forum for Injection Technique and Therapy: Expert Recommendations
G gauge (of needle).
GCP good clinical practice.
GLP-1 glucagon-like peptide-1 receptor agonists
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HbA1c glycated hemoglobin
HBV hepatitis B virus
HCP health care professional
HCV hepatitis C virus
ID intradermal
IM intramuscular
ITQ injection technique questionnaire
IU international unit (of insulin)
LH− patient without lipohypertrophy
LH lipohypertrophy
LH+ patient with lipohypertrophy
NPH neutral protamine hagedorn (also known as insulin N)
NSI needle-stick injury
PD pharmacodynamics
PK pharmacokinetics.
SC subcutaneous
T1DM type 1 diabetes
T2DM type 2 diabetes.
TDD total daily dose (of insulin)
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